In established infection, interventions that primarily target innate pathways—such as STING agonists, TLR7 agonists, and selected ncRNA-based strategies—are being developed not simply to further amplify cytokine output, but to better control the spatial and temporal dimensions of interferon signaling. The gene discussed is TLR7; the disease is infection.